Dean F. Bajorin, MD
Genitourinary Medical Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Request an Appointment
About Me
- Frederick R. Adler Senior Faculty Chair
My expertise is in the treatment of genitourinary tumors — particularly bladder and testicular cancers. As a member of Memorial Sloan Kettering Cancer Center’s Genitourinary Oncology faculty since 1986, I have diagnosed and treated thousands of people with these cancers.
Read more
In addition to treating patients, I have researched new drugs (and combinations of drugs) for people who have developed advanced bladder cancer and other genitourinary malignancies. My research has been directed toward improving treatment with chemotherapy, targeted drugs, and novel immunotherapy drugs; evaluating biological characteristics of tumors to predict treatment response; and understanding the genetic basis for both treatment response and development of urothelial cancers. I have served as the principal investigator on research grants from the National Cancer Institute for translational research in urothelial cancer as well as currently serving as a principal investigator for the MSK P50 SPORE in Bladder Cancer. I am a reviewer for several major journals on testicular and bladder cancer and have authored or coauthored more than 350 medical manuscripts.
I have had a life-long commitment to medical education. As director of the Medical Oncology/Hematology Fellowship Training Program since 1994, I help oversee the training of generations of leaders in cancer treatment and research. I serve as the principal investigator of the Department of Medicine’s NIH T32 grant that trains medical oncology and hematology fellows for a career in translational cancer research. I have directed the Clinical Research Methodology Curriculum for training clinical investigators in human subject research since 1999 and currently serve as the co-principal investigator for the Educational Core of the Weill Cornell Medical Center’s Clinical and Translational Science Award funded by the National Institute of Health. I am also past Chair for the American Society of Clinical Oncology (ASCO) Fellowship Training and Professional Development Committees focused on life-long learning for physicians who treat cancer.
I am proud to have received a number of honors and awards for my work, including the MSK’s Willet Whitmore Award for Excellence in Patient Care and the ASCO Statesmen Award, which recognizes certain members for more than 20 years of extraordinary volunteer service, dedication, and commitment. Among other contributions, I also helped ASCO shape a new strategic plan to address the looming shortage of oncologists in the United States by 2020 — including the development of innovative practice arrangements.
A genitourinary (jeh-nih-toh-YOOR-ih-nayr-ee) medical oncologist is a cancer doctor who specializes in genitourinary (GU) cancers. This includes bladder, kidney, penis, prostate, and testicular cancers.
My Specialties
- Bladder Cancer
- Testicular Cancer
- Prostate Cancer
- Other Genitourinary Cancers
- Immunotherapy
Education
- MD, New York Medical College
Residencies
- Internal Medicine - Hartford Hospital
Awards and Honors
- Castle Connolly: America’s Top Doctor (2024)
- Top Doctors New York Metro Area, Castle Connolly (2023)
- Castle Connolly: America's Top Doctors (2023)
- Castle Connolly: New York Magazine Top Doctors (2010, 2015-2020)
Fellowships
- Medical Oncology - Memorial Sloan Kettering Cancer Center
- Medicine - Cornell University Medical Center
Board Certifications
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Bajorin sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Bajorin
- A Phase II Study of Pembrolizumab Immunotherapy and BCG as Initial Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cancer
- Clinical Trials Co-Investigated by Dr. Bajorin
- A Phase II Study of Chemotherapy without Surgery in Patients with Muscle-Invasive Bladder Cancer and Certain Gene Mutations
- A Pilot Study Assessing Immunotherapy with Nivolumab Alone or with Ipilimumab Before Surgery for Patients with Muscle-invasive Bladder Cancer Who Cannot Have Cisplatin-Based Chemotherapy
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Bajorin’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Dean F. Bajorin discloses the following relationships and financial interests:
-
Bristol-Myers Squibb
Professional Services and Activities (Uncompensated)
-
Merck & Co Inc.
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.